CSF3 and non-Hodgkin lymphoma: Since then, numerous clinical trials have been carried out either as monotherapy or in combination with other drugs, especially for untreated or relapsed/refractory acute myeloid leukemia (r/r AML) (NCT01455025); non-Hodgkin’s lymphoma and multiple myeloma (MM) (NCT00322842, using AMD3100 + granulocyte colony-stimulating factor (G-CSF)) [62]; r/r MM (NCT00903968, using AMD3100 + Bortezomib) [63].